These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 25679077)

  • 21. Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing central compartment neck dissection for squamous cell carcinoma of the larynx, hypopharynx, and esophagus.
    Kim JW; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2013 May; 49(5):449-53. PubMed ID: 23321549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluorodeoxyglucose positron emission tomography with computed tomography detects greater metabolic changes that are not represented by plain radiography for patients with osteonecrosis of the jaw.
    Fleisher KE; Raad RA; Rakheja R; Gupta V; Chan KC; Friedman KP; Mourtzikos KA; Janal M; Glickman RS
    J Oral Maxillofac Surg; 2014 Oct; 72(10):1957-65. PubMed ID: 25053572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. (18)F-FDG PET/CT imaging in granulomatosis with polyangiitis.
    De Geeter F; Gykiere P
    Hell J Nucl Med; 2016; 19(1):5-6. PubMed ID: 26929934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-FDG-PET/CT better localizes active spinal infection than MRI for successful minimally invasive surgery.
    Nakahara M; Ito M; Hattori N; Magota K; Takahata M; Nagahama K; Sudo H; Kamishima T; Tamaki N; Iwasaki N
    Acta Radiol; 2015 Jul; 56(7):829-36. PubMed ID: 25080515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantification of supra-aortic arterial wall inflammation in patients with arteritis using high resolution dynamic contrast-enhanced magnetic resonance imaging: initial results in correlation to [18F]-FDG PET/CT.
    Cyran CC; Sourbron S; Bochmann K; Habs M; Pfefferkorn T; Rominger A; Raya JG; Reiser MF; Dichgans M; Nikolaou K; Hacker M; Saam T
    Invest Radiol; 2011 Sep; 46(9):594-9. PubMed ID: 21577125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
    Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
    Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
    Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
    J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the effect of positive and negative oral contrast agents on (18)F-FDG PET/CT scan.
    Sun XG; Huang G; Liu JJ; Wan LR
    Hell J Nucl Med; 2009; 12(2):115-8. PubMed ID: 19675862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
    Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
    Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Negative
    Van de Wiele C; Verstraete K; Bourgeois S; Maes A
    Hell J Nucl Med; 2017; 20(2):182-183. PubMed ID: 28697199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does 18F-FDG PET/MRI reduce the number of indeterminate abdominal incidentalomas compared with 18F-FDG PET/CT?
    Schaarschmidt BM; Grueneisen J; Heusch P; Gomez B; Umutlu L; Ruhlmann V; Rosenbaum-Krumme S; Antoch G; Buchbender C
    Nucl Med Commun; 2015 Jun; 36(6):588-95. PubMed ID: 25759944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantification of inflammation within rabbit atherosclerotic plaques using the macrophage-specific CT contrast agent N1177: a comparison with 18F-FDG PET/CT and histology.
    Hyafil F; Cornily JC; Rudd JH; Machac J; Feldman LJ; Fayad ZA
    J Nucl Med; 2009 Jun; 50(6):959-65. PubMed ID: 19443582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical values of (18) F-FDG PET/CT in oral cavity cancer with dental artifacts on CT or MRI.
    Hong HR; Jin S; Koo HJ; Roh JL; Kim JS; Cho KJ; Choi SH; Nam SY; Kim SY
    J Surg Oncol; 2014 Nov; 110(6):696-701. PubMed ID: 24995957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A comparison with FDG-PET/CT.
    Tsuji K; Kishi S; Tsuchida T; Yamauchi T; Ikegaya S; Urasaki Y; Fujiwara Y; Ueda T; Okazawa H; Kimura H
    J Magn Reson Imaging; 2015 Jun; 41(6):1601-7. PubMed ID: 25111444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
    Jadvar H; Henderson RW; Conti PS
    J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on advances in molecular PET in urological oncology.
    Kitajima K; Yamamoto S; Fukushima K; Minamimoto R; Kamai T; Jadvar H
    Jpn J Radiol; 2016 Jul; 34(7):470-85. PubMed ID: 27222021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beyond 18F-FDG: Characterization of PET/CT and PET/MR Scanners for a Comprehensive Set of Positron Emitters of Growing Application--18F, 11C, 89Zr, 124I, 68Ga, and 90Y.
    Soderlund AT; Chaal J; Tjio G; Totman JJ; Conti M; Townsend DW
    J Nucl Med; 2015 Aug; 56(8):1285-91. PubMed ID: 26135111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of relapse in patients with peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using F-18-FDG-PET/CT.
    Klumpp B; Schwenzer NF; Gatidis S; Koenigsrainer I; Koenigsrainer A; Beckert S; Mueller M; Claussen CD; Pfannenberg C
    Rofo; 2014 Apr; 186(4):359-66. PubMed ID: 24683168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
    van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
    J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pulmonary mucosa-associated lymphoid tissue lymphoma: computed tomography and ¹⁸F fluorodeoxyglucose-positron emission tomography/computed tomography imaging findings and follow-up.
    Zhang WD; Guan YB; Li CX; Huang XB; Zhang FJ
    J Comput Assist Tomogr; 2011; 35(5):608-13. PubMed ID: 21926857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.